ABSTRACT
Background Homeostatic physiologic systems are regulated to maintain a particular variable such as blood pressure within a restricted range with relatively low variation, and this variation is increased with disease. Fractal physiologic systems, on the other hand, are characterized by wide, complex variation of variables such as heart rate or the walking stride interval, and this variation is decreased with disease. The present report examines time-series recordings of esophageal pH from normal subjects and different GERD phenotypes to measure the distributions of esophageal pH values and the distributions of changes in esophageal acid concentrations.
Methods Using Lyon consensus definitions of symptomatic GERD phenotypes, I analyzed 24-hour esophageal pH recordings from normal subjects (n=20), Functional Heartburn subjects (n=20), Reflux Hypersensitivity subjects (n=20), and nonerosive esophageal reflux disease (NERD) subjects (n=20). For each subject I calculated the distribution of pH values as well as the distribution of changes in esophageal acid concentrations.
Results Esophageal pH values have a power law distribution in both normal and symptomatic GERD phenotypes, and esophageal acid concentrations vary over four orders of magnitude in each group. The variation in esophageal acid concentrations decreased progressively from normal subjects to Functional Heartburn subjects to Reflux Hypersensitivity subjects to NERD subjects.
Conclusions The decreased variation in esophageal acid concentration in symptomatic GERD phenotypes represents changes associated with disease in a fractal physiologic system that shares characteristic features with other fractal systems where disease states have been associated with decreased variation of heart rate or walking stride interval.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
: For this retrospective analysis of clinically indicated tests with no identifiable patient data, the Stanford University Institutional Review Board determined that this research does not involve human subjects as defined in 45 CFR 46.102(f) or 21 CFR 50.3 (g).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The work described in this manuscript has not been published and is not being considered for publication elsewhere.
Conflict of Interest Statement: Dr. Gardner is President of Science for Organizations (www.scifororg.com), a company that provides consulting services to biotechnology and pharmaceutical companies. These activities have no conflict of interest with the analyses in the present paper.
Ethics Approval: For this retrospective analysis of clinically indicated tests with no identifiable patient data, the Stanford University Institutional Review Board determined that this research does not involve human subjects as defined in 45 CFR 46.102(f) or 21 CFR 50.3 (g).
All data produced in the present study are available upon reasonable request to the authors.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
